Country: South Africa
Language: English
Source: South African Health Products Regulatory Authority (SAHPRA)
Lennon
PETERKAÏEN 2% m/v INJECTION 2 mL PETERKAÏEN 2% m/v INJECTION 5 mL SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): PETERKAÏEN 2% m/v INJECTION 2 mL PETERKAÏEN 2% m/v INJECTION 5 mL COMPOSITION Each 2 mL ampoule contains 0,04 g Lignocaine Hydrochloride Monohydrate Each 5 mL ampoule contains 0,1 g Lignocaine Hydrochloride Monohydrate PHARMACOLOGICAL CLASSIFICATION A 4 Local anaesthetics PHARMACOLOGICAL ACTION Lignocaine has local anaesthetic action (it blocks conduction of nerve impulses by decreasing or preventing the large transient increase in permeability of the cell membrane to sodium ions) and antiarrhythmic properties, last mentioned, as a result of its direct influence on the depolarising of the cardiac membrane. It increases the electrical stimulation threshold of the ventricle during diastole. INDICATIONS Treatment of ventricular arrhythmias during open-heart surgery, acute myocardial infarction and after digoxin overdosage. As a local anaesthetic in infiltration, field block, nerve block, intravenous regional and spinal anaesthesia. As a local anaesthetic it has an action of intermediate duration (30 to 45 minutes). CONTRA-INDICATIONS Contra-indicated in patients that are hypersensitive to local anaesthetics. Lignocaine hydrochloride should not be given to patients with hypovolaemia, heartblock or other conduction disturbances, bradycardia, cardiac decompensation or hypotension. WARNINGS Intravenous injections should be given slowly over 2 minutes and infusion at a rate of 1 to 4 mg per minute. DOSAGE AND DIRECTIONS FOR USE For the emergency treatment of acute myocardial infarction doses of up to 300 mg may be given by intramuscular injection into the deltoid muscle, followed by a 0,1% to 0,2% intravenous infusion (in Dextrose 5% in Water for Injections) at a r Read the complete document